AZN: H1 2020 results
AstraZeneca PLC 30 July 2020 07:00 BST H1 2020 results A strong performance during the pandemic; a leader in the fight against COVID-19 During the COVID-19 global pandemic, AstraZeneca's priority was and will continue to be the safe supply of medicines to millions of patients. In the first half, revenue, profit and cash-flow continued to grow. This performance was supported by successful launches of new medicines[1] and more encouraging progress from the pipeline. The Company's focus on growth through innovation is designed to support a continuation of these trends. Pascal